Preparing for dengue vaccine introduction in ASEAN countries: Recommendations from the first ADVA regional workshop

Expert Review of Vaccines

Volumn 13, Issue 5, 2014, Pages 581-587

  Thisyakorn, Usa ^a   Capeding, Maria R ^b   Goh, Daniel Yam Thiam ^c   Hadinegoro, Sri Rezeki ^d   Ismail, Zulkifli ^e   Tantawichien, Terapong ^a   Yoksan, Sutee ^f   Pang, Tikki ^g  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF INDONESIA   (Indonesia)

^e Flight Technology and Testing Centre FTTC UiTM   (Malaysia)

^f MAHIDOL UNIVERSITY   (Thailand)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Association of South East Asian Nations; burden; dengue; Southeast Asia; surveillance; vaccination impact; vaccine introduction

Indexed keywords

DENGUE VACCINE;

DENGUE; DIAGNOSTIC TEST; HUMAN; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SOUTHEAST ASIA; VACCINATION; WORLD HEALTH ORGANIZATION; EDUCATION; EPIDEMIOLOGY; HEALTH CARE PLANNING; TRENDS;

ASIA, SOUTHEASTERN; DENGUE; DENGUE VACCINES; EDUCATION; HEALTH PLANNING GUIDELINES; HUMANS;

EID: 84921311236     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.907529     Document Type: Review

References (23)

1. WHO. Global strategy for dengue prevention and control 2012-2020. World Health Organisation; Geneva, Switzerland; 2012. p. vi, 43 p
2. Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of dengue in Southeast Asia. PLoS Negl Trop Dis 2013; 7(2):e2055
3. ASEAN. Joint Statement of the 10th ASEAN Health Ministers Meeting Singapore. 2010. Available from: Www. asean.org/news/item/joint-statement-of- The-10th-Asean-health-ministers [Accessed 6 November 2013]
4. ASEAN. Yangon Call for Action on the Prevention and Control of Dengue 15th June 2012, Yangon, Republic of the Union of Myanmar. Available from: Www.asean. org/news/asean-secretariat-news/item/yangon-call-for-Action-on-The- preventionand-control-of-dengue-15th-june-2012-yangon-republic-of-The-union-of- myanmar [Accessed 6 November 2013]
5. Lam SK, Burke D, Capeding MR, et al. Preparing for introduction of a dengue vaccine: Recommendations from the 1st Dengue v2V Asia-Pacific Meeting. Vaccine 2011;29:9417-22
6. Hanna JN. Dengue Vaccines: Introduction and Delivery Issues. PDVI Occasional Paper 2, September 2010
7. Beatty ME, Stone A, Fitzsimons DW, et al. Best practices in dengue surveillance: A report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS NTD 2010;4(11):e890
8. Thisyakorn U. ADVASC-New regional initiative supporting transition from dengue vaccine to vaccination in Southeast Asia. Vaccine 2012;30(38):5587-8
9. Glass RI, Parashar UD, Bresee JS, et al. Rotavirus vaccines: Current prospects and future challenges. Lancet 2006;368(9532): 323-32
10. ROTA Council. Rotavirus disease burden and vaccine introduction maps. Available from: Http://rotacouncil.org/rotavirusburden-vaccine-introduction-map/ [Accessed 6 November 2013]
11. Ruiz-Palacios G M, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354(1):11-22
12. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354(1):23-33
13. Capeding RZ, Luna IA, Bomasang E, et al. Live-Attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines. Vaccine 2011;29(22):3863-72
14. Poo J, Galan F, Forrat R, et al. Live-Attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico city: Randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2010; 30(11):e9-e17
15. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-Attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 2012;380(9853):1559-67
16. Schaffner W. Update on vaccine-preventable diseases: Are adults in your community adequately protected? J Fam Pract 2008; 57(4 Suppl):S1-11.quiz S12
17. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: New paradigms for protection. Clin Infect Dis 2008;47(10): 1328-38
18. WHO. Dengue haemorrhagic fever: Diagnosis, treatment, prevention and control. 2nd edition. World Health Organization; Geneva: 1997
19. WHO. Dengue: Guidelines for diagnosis, treatment, prevention and control. New edition. World Health Organization; Geneva: 2009
20. Srikiatkhachorn A, Rothman AL, Gibbons RV, et al. Dengue-how best to classify it. Clin Infect Dis 2011;53(6):563-7
21. WHO Regional office for South-East Asia. Comprehensive guidelines for prevention and control of dengue and dengue hemorrhagic fever. Revised and expanded edition. 2011. Available from: Www.searo. who.int/entity/vector-borne- Tropical-diseases/documents/SEAROTPS60/en/index. html [Accessed 7 November 2013]
22. Peeling RW, Artsob H, Pelegrino JL, et al. Evaluation of diagnostic tests: Dengue. Nat Rev Microbiol 2010;8(12 Suppl):S30-8
23. Thomas SJ. The necessity and quandaries of dengue vaccine development. J Infect Dis 2011;203(3):299-303